MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting

Clinical Infectious Diseases

Volumn 58, Issue 9, 2014, Pages 1219-1226

  Ostrosky Zeichner, Luis ^a   Shoham, Shmuel ^b   Vazquez, Jose ^c   Reboli, Annette ^d   Betts, Robert ^e   Barron, Michelle A ^f   Schuster, Mindy ^g   Judson, Marc A ^h   Revankar, Sanjay G ⁱ   Caeiro, Juan Pablo ^j   Mangino, Julie E ^k   Mushatt, David ^l   Bedimo, Roger ^m   Freifeld, Alison ⁿ   Nguyen, Minh Hong ^o   Kauffman, Carol A ^p   Dismukes, William E ^q   Westfall, Andrew O ^r   Deerman, Jeanna Beth ^q   Wood, Craig ^s   Sobel, Jack D ⁱ   Pappas, Peter G ^q   more..

^a UNIVERSITY OF TEXAS   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AUGUSTA UNIVERSITY   (United States)

^d Cooper Medical School of Rowan University ^*  (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h ALBANY MEDICAL COLLEGE   (United States)

ⁱ WAYNE STATE UNIVERSITY   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Veterans Affairs North Texas Health Care System   (United States)

ⁿ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^o UNIVERSITY OF PITTSBURGH   (United States)

^p UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^q University of Puerto Rico Medical Sciences Campus   (Puerto Rico)

^r UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^s MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

caspofungin; ICU; invasive candidiasis; preemptive therapy; prophylaxis

Indexed keywords

1,3 BETA GLUCANASE; ANTIBIOTIC AGENT; CASPOFUNGIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO; STEROID; ANTIFUNGAL AGENT; ECHINOCANDIN;

ABDOMINAL ABSCESS; ADULT; ANTIBIOTIC THERAPY; ANTIFUNGAL PROPHYLAXIS; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CENTRAL VENOUS CATHETER; CHILD PUGH SCORE; CONTROLLED STUDY; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG THERAPY; EDEMA; EMPYEMA; ENZYME BLOOD LEVEL; ESOPHAGUS INJURY; FACE DISORDER; FEMALE; FLUSHING; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PARENTERAL NUTRITION; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; SYSTEMIC THERAPY; AGED; CANDIDIASIS, INVASIVE; INCIDENCE; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; DOUBLE-BLIND METHOD; ECHINOCANDINS; FEMALE; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84898922226     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu074     Document Type: Article

References (18)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H,Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17
2. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7
3. Rex JH, Wingard JR, Wenzel R, Herbrecht R, Sobel J, Edwards JE Jr. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: Introduction and overview. Clin Infect Dis 2004; 39(suppl 4):S165-9
4. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: A metaanalysis. Crit Care Med 2005; 33:1928-35; quiz 36
5. Ostrosky-Zeichner L. Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit?. Crit Care Med 2004; 32:2552-3
6. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35
7. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-Abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-72
8. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-17
9. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebocontrolled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-8
10. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: Systematic review and meta-Analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57:628-38
11. De Pauw B,Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21
12. Ostrosky-Zeichner L, Pappas PG, Shoham S, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011; 54:46-51
13. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-6
14. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Beta-D-glucan assay for the diagnosis of invasive fungal infections: A meta-Analysis. Clin Infect Dis 2011; 52:750-70
15. Garey KW, Rege M, PaiMP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006; 43:25-31
16. Hanson KE, Pfeiffer CD, Lease ED, et al. Beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: A randomized pilot study. PLoS One 2012; 7: E42282
17. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: The first in a new class of antifungal agents. Drug Resist Updat 2003; 6:197-218
18. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.